Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-PD1 Activated TILs and Chemotherapy in Stage III Colorectal Cancer
NCT03904537Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2019
- Primary completion
- Dec 2019
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anti-PD-1 antibody-activated tumor-infiltrating lymphocytes in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Primary endpoint: Disease-free survival at 6 months. Status: unknown.
02
Drugs
anti-PD-1 antibody-activated tumor-infiltrating lymphocytes
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03904537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904537.